Showing results (1-10 of 57) with videos related to

Sort By:
Pageof 6
Expert Review of Pharmacoeconomics & Outcomes Research|November 13, 2015
Whose preferences should be elicited for use in health-care decision-making? A case study using anticoagulant therapyDavid John Mott, Mehdi Najafzadeh
BMC Infectious Diseases|October 22, 2016
Increasing incidence associated with herpes zoster infection in British Columbia, CanadaFawziah Marra, Mei Chong, Mehdi Najafzadeh
Pharmacoeconomics|November 8, 2017
Economic Evaluation of Implementing a Novel Pharmacogenomic Test (IDgenetix<sup>®</sup>) to Guide Treatment of Patients with Depression and/or AnxietyMehdi Najafzadeh, Jorge A Garces, Alejandra Maciel
Clinical Pharmacology and Therapeutics|October 17, 2017
Synergies From Integrating Randomized Controlled Trials and Real-World Data AnalysesMehdi Najafzadeh, Joshua J Gagne, Sebastian Schneeweiss
Journal of Clinical Epidemiology|May 20, 2008
Reliability studies of diagnostic tests are not using enough observers for robust estimation of interobserver agreement: a simulation studyMohsen Sadatsafavi, Mehdi Najafzadeh, Larry Lynd, et al.
Personalized Medicine|January 11, 2014
Bumps along the translational pathway: anticipating uptake of tailored smoking cessation treatmentAlexandra Elizabeth Shields, Mehdi Najafzadeh, Anna Boonin Schachter
American Journal of Medical Genetics. Part A|February 28, 2013
Barriers for integrating personalized medicine into clinical practice: a qualitative analysisMehdi Najafzadeh, Jennifer C Davis, Pamela Joshi, et al.
Pharmacoepidemiology and Drug Safety|July 6, 2010
A quantitative evaluation of the regulatory assessment of the benefits and risks of rofecoxib relative to naproxen: an application of the incremental net-benefit frameworkLarry D Lynd, Carlo A Marra, Mehdi Najafzadeh, et al.
Pharmacoeconomics|November 14, 2009
Cost effectiveness of herpes zoster vaccine in CanadaMehdi Najafzadeh, Carlo A Marra, Eleni Galanis, et al.
BMJ (Clinical Research Ed.)|July 19, 2019
Spending on World Health Organization essential medicines in Medicare Part D, 2011-15: retrospective cost analysisDavid G Li, Mehdi Najafzadeh, Aaron S Kesselheim, et al.
Pageof 6